THE SAFETY AND EFFICACY OF CONVERSION FROM CALCINEURIN INHIBITORS TO mTOR INHIBITORS IN STABLE KIDNEY TRANSPLANT RECIPIENTS

被引：0
|
作者：
Asanga, Abeyaratne [1 ]
Michael, Collins [1 ]
Kym, Bannister [1 ]
Graeme, Russ [1 ]
机构：
[1] Royal Adelaide Hosp, Renal & Transplantat Unit, Cent No Adelaide Renal & Transplantat Serv, Adelaide, SA, Australia
来源：
IMMUNOLOGY AND CELL BIOLOGY | 2012年 / 90卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：A1 / A1
页数：1
相关论文
共 50 条
  • [41] Calcineurin inhibitors in pediatric renal transplant recipients
    Filler G.
    Pediatric Drugs, 2007, 9 (3) : 165 - 174
  • [42] mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases
    Johnson, Simon C.
    Martinez, Frank
    Bitto, Alessandro
    Gonzalez, Brenda
    Tazaerslan, Cagdas
    Cohen, Camille
    Delaval, Laure
    Timsit, Jose
    Knebelmann, Bertrand
    Terzi, Fabiola
    Mahal, Tarika
    Zhu, Yizhou
    Morgan, Philip G.
    Sedensky, Margaret M.
    Kaeberlein, Matt
    Legendre, Christophe
    Suh, Yousin
    Canaud, Guillaume
    KIDNEY INTERNATIONAL, 2019, 95 (02) : 455 - 466
  • [43] Late Conversion from Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
    Noble, J.
    Terrec, F.
    Jouve, T.
    Bennani, H. Neciri
    Benhamou, P.
    Malvezzi, P.
    Janbon, B.
    Giovannini, D.
    Rostaing, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 927 - 927
  • [44] Immunological Monitoring of Calcineurin Inhibitors for Predicting Cytomegalovirus Infection in Kidney Transplant Recipients
    Couzi, Lionel
    Thiebaut, Rodolphe
    Carron, Jean-Claude
    Moreau, Jean-Francois
    Merville, Pierre
    Taupin, Jean-Luc
    TRANSPLANTATION, 2008, 86 (08) : 1060 - 1067
  • [45] Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
    Terrec, Florian
    Jouve, Thomas
    Naciri-Bennani, Hamza
    Benhamou, Pierre-Yves
    Malvezzi, Paolo
    Janbon, Benedicte
    Giovannini, Diane
    Rostaing, Lionel
    Noble, Johan
    TRANSPLANTATION DIRECT, 2020, 6 (01): : E517
  • [46] Cardiovascular Disease Markers in Kidney Transplant Recipients Converted from Calcineurin Inhibitors to Everolimus.
    Schiavelli, R.
    Cuevas, C.
    Alvarenga, E.
    Ponte, M.
    Otero, A.
    Margulis, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 315 - 315
  • [47] THE EFFECTS OF CALCINEURIN INHIBITORS ON SPERM DNA FRAGMENTATION IN MALE KIDNEY TRANSPLANT RECIPIENTS
    Ersoy, Alparslan
    Samli, Hale
    Gul, Cuma Bulent
    Samli, Murat
    Ardicli, Sena
    Balci, Faruk
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [48] Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients
    Felipe, Claudia
    Ferreira, Alexandra
    Bessa, Adrieli
    Abait, Tamiris
    Perez, Juliana D.
    Casarini, Dulce Elena
    Medina-Pestana, Jose
    Tedesco, Helio
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 52 - 58
  • [49] Safety and Efficacy of Anti Xa Inhibitors Post-Transplant with Concomitant Calcineurin Inhibitors.
    McMurry, K. A.
    Shuster, J.
    Bain, K.
    Horwedel, T.
    Hartupee, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 1109 - 1109
  • [50] Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation
    Asante-Korang, Alfred
    Carapellucci, Jennifer
    Krasnopero, Diane
    Doyle, Abigail
    Brown, Brian
    Amankwah, Ernest
    CLINICAL TRANSPLANTATION, 2017, 31 (10)
12345